6533b861fe1ef96bd12c5014

RESEARCH PRODUCT

Efficacy and safety of photodynamic therapy with RLP068 for diabetic foot ulcers: a review of the literature and clinical experience

Carmelo LicciardelloFelicia PantòCarla GiordanoLiboria Adamo

subject

rlp0680301 basic medicinemedicine.medical_specialtymedicine.medical_treatment030106 microbiologyPhotodynamic therapyReviewantimicrobial therapy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDiabetes mellitusmedicinePharmacologyulcerdiabetesbusiness.industrylcsh:RM1-950General MedicineAntimicrobialmedicine.diseaseDermatologyDiabetic footPhthalocyanine derivativesClinical triallcsh:Therapeutics. Pharmacologyphotodynamic therapyMolecular MedicineWound healingbusiness

description

This article is the second part of a literature review concerning diabetic foot ulcers (DFUs) and the use of antimicrobial photodynamic therapy (PDT). PDT involves the topical application of a photosensitiser into the tissue, followed by illumination that induces the formation of reactive oxygen species (ROS). PDT provides bacterial inactivation and promotes wound healing, and it can be used to manage the infection and microbial colonisation of DFUs. It has pivotal advantages in comparison with chemotherapeutics, such as no potential to induce resistance, and a wide spectrum of activity. Tetracationic Zn(II) phthalocyanine derivatives have been developed for PDT. Among these, we would like to focus on RLP068, whose antimicrobial activity has been widely demonstrated in preclinical studies and in a clinical trial. This article reports previously published evidence and presents four unpublished clinical cases of DFUs treated in the real-life setting with PDT.

https://doi.org/10.7573/dic.2019-10-3